Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line osimertinib followed by sequential chemotherapy and immunotherapy in EGFR-mutant advanced lung adenocarcinoma
ChiCTR2000041206Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Chinese PLA General Hospital. Primary endpoint: 2-year progression-free survival rate. Started Dec 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000041206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041206.